



Newsletter from Emotra AB (publ)

Göteborg, February 18, 2016

## A short update from Emotra – Kickoff for Horizon 2020 and a conference in Madrid

**Emotra is in the midst of a very intensive phase. To date, 1,460 patients have been tested in our ongoing study, and we will soon stop accepting new EDOR test data for patients. On March 7, Emotra's scientific advisers and collaboration partners will meet with the Spanish company Inspiralia in Munich, Germany to plan the launch of our Horizon 2020, Phase I study. On March 12–15, Emotra will be participating at the European Psychiatric Association's international conference in Madrid, Spain, where a special symposium on EDOR is being arranged.**

The symposium will be led by EDOR's inventor and Emotra's Research Manager, Dr. Lars-Håkan Thorell, and Emotra's scientific advisor, Professor Marco Sarchiapone, from Molise, Italy.

EDOR will be the subject of a number of other presentations this year, by both Lars-Håkan Thorell and professor Marco Sarchiapone. In addition to presentations in Madrid, several presentations will be held during the international suicide convention in Oviedo in September. Emotra will also be holding presentations at a number of other international and domestic psychiatric conferences, mainly in Europe, but also in Sao Paulo, Brazil, in August, 2016.

In connection with the conferences in Madrid in March and Oviedo in September, Emotra will be arranging follow-up meetings with the clinics involved in the study. The Company's other preparations for our planned international product launch are proceeding according to plan.

The European multi-centre study on the use of EDOR for assessing suicide risk, which Emotra is conducting in close collaboration with the European Psychiatric Association's Suicide Section, EPA-SS, is proceeding according to plan. To date, test data for 1,460 patients have been submitted to Emotra for analysis. At the present inflow rate, testing of new patients will not need to continue for more than a few weeks at most.

On March 7, Emotra's scientific advisers, collaboration partners and the Madrid-based company Inspiralia will participate in a kickoff meeting for Phase I of our Horizon 2020 study. Inspiralia has approximately 100 employees and is specialised in Phase I studies. Emotra, Marco Sarchiapone and Dr Vladimir Carli, a prominent suicide researcher at the Karolinska Institute, will be responsible for authoring the scientific, clinical and health care-related content, while Inspiralia will be responsible for carrying out the planned feasibility study and for reporting the study and its results to the European Commission. Our ambition is that Inspiralia will be compiling the application for Phase II, which is a study on children and young people up to 20 years of age.

---

***Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.***

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)



**For further information, please contact:** Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden  
Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)